SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares are facing significant downward pressure following an orbital insertion failure during a Blue Origin launch that resulted in the loss of a satellite. While the community is actively debating the reliability of launch partners and the impact on the companys ambitious deployment roadmap, long-term investors are focused on insurance coverage and existing manufacturing pipelines as key catalysts for a potential rebound.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating intense market attention as traders bet on a short squeeze and potential industry-wide transformation following an executive order from the U.S. government regarding the expedited research and development of psychedelic therapies. The community is heavily focused on the stock's low float, aggressive institutional interest, and the belief that the company's GMP-compliant ibogaine supply chain positions it as a critical player in a rapidly expanding mental health sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following a massive $2.8 billion acquisition of Serra Verde Group, a move the market views as a strategic play to become a dominant, non-Asian leader in the rare earth supply chain. While investors are debating the impacts of the associated share dilution, community sentiment is largely focused on the company's long-term potential to anchor the Western EV and defense infrastructure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is gaining momentum as retail investors and the community ramp up activity ahead of the upcoming AACR conference, where new data for the SLS009 platform will be presented. Supporters are actively discussing the potential for a significant price movement driven by heavy call option positioning and large-scale short interest, while long-term investors remain focused on the clinical potential of the GPS pivotal Phase 3 study.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is seeing intense trading activity and community speculation driven by the anticipation of Phase 2b data for rezpegaldesleukin in alopecia areata, which remains a key binary event for the company. While the community is actively debating the potential for a clinical breakthrough, a lucrative partnership, or a legal settlement with Eli Lilly, traders are closely monitoring price volatility ahead of these major upcoming catalysts.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently a focal point for investors as the community debates the impact of potential trade enforcement, ongoing industry consolidation rumors, and the CEO's recent strategic maneuvers. While some market participants are optimistic about the company's vertically integrated position and the long-term potential for a POSCO partnership, others are expressing significant caution regarding the company's debt levels and recent insider selling activity.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum and investor interest as the community points to strong clinical trial data, the upcoming BLA submission, and a highly undervalued market cap relative to its pipeline potential. Investors are actively discussing the possibility of a buyout or strategic partnership, with many viewing current price levels as an accumulation opportunity ahead of key data catalysts.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to its role as a key U.S.-based, vertically integrated rare earth producer amidst intensified geopolitical tensions and national security concerns. Community discussion is heavily focused on the company's long-term supply chain importance, its recent appearance on a major television segment, and the broader implications of U.S. government policy supporting domestic critical mineral independence.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as a major play in the psychedelic medicine space following a presidential executive order that fast-tracks federal research and access for treatments like psilocybin. The community is actively debating the potential for an FDA approval breakthrough for the company's leading COMP360 candidate, with many investors closely tracking the regulatory tailwinds alongside sentiment from key institutional backers.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynex Capital is seeing heightened investor interest as the community navigates the company's recent dividend payments and shifting book value, with many discussing the impact of interest rate environments on its mortgage REIT business model. Discussions are largely split between long-term holders seeking consistent monthly passive income and traders debating the stock's valuation as it trades in a lower range relative to historical averages.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for...

Galmed Stock Soars On Brain-Penetrating Aramchol Formulation

Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain penetrating new formulation of Aramchol.read more...

These Stocks are Turning Heads

A wave of innovation across AI robotics, biotechnology, advanced materials, and clean energy is reshaping the small-cap landscape. $ONCO, $KBLB, $ELAB, $GLMD, $TURB, $GAME

<ul class="summary-bullets"><li>The new Aramchol formulation uses lipid nanoparticles delivered via injection and is designed to cross the blood–brain barrier.</li><li>Initial data showed that Aramchol reduced harmful protein buildup without causing toxicity.</li><li>The formulation was developed in collaboration with Barcode Nanotech.</li></ul>Shares of Galmed Pharmaceuticals (GLMD) soared more than 55% on Thursday, after the biotech firm launched a new brain-penetrating formulation of its flagship drug Aramchol.<a href="https://stocktwits.com/symbol/GLMD">GLMD stock</a> climbed above $1 for the first time since December 19. Thursday’s rally comes after a 27% gain over the last five sessions.The upmove comes at a crucial time as Galmed has struggled to remain compliant with Nasdaq’s listing rules. On Jan. 30, 2026, the company received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement. Galmed was given 180 days to regain compliance, with the deadline on July 28, 2026.<h2 class="st-heading-2">Early Data Shows Promise In Preventing Disease Progression</h2>The new Aramchol formulation uses lipid nanoparticles delivered via injection and is designed to cross the blood–brain barrier (BBB), a major obstacle that prevents most drugs from reaching the brain. This can be especially useful to treat central nervous system disorders like Parkinson’s disease.Initial data showed that Aramchol reduced harmful protein buildup (α-synuclein) without causing toxicity. This suggests it could help slow or prevent disease progression. The formulation was developed in collaboration with Barcode Nanotech.“Subject to the regulatory advice we are now seeking, we are planning to advance Aramchol to a PoC Ph1b/2 studies in PD patients in H2 2026,” said Allen Baharaff, Galmed's Co-founder and CEO.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, accompanied by ‘extremely high’ message volumes.One user said the stock was consolidating ahead of the next rally. GLMD shares had gained more than 70% after the opening bell.<stembedurl>https://stocktwits.com/Changinc/message/649819751</stembedurl>Year-to-date, the stock has gained more than 12%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GLMD Stock Shot Up 55% Today After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy?

The biotech firm launched a new formulation of its investigational therapy, which could help treat Parkinson’s disease.

Equity

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol Galmed Announces the Breakthrough Development of a Brain Penetrating New...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel, Jan...

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH Galmed Announces Grant of New Use Patents for the combination...

Galmed Issues CEO Letter to Shareholders

Galmed Issues CEO Letter to Shareholders Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel, Dec. 1, 2025 TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd...

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

GLMD
Galmed Pharmaceuticals Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest GLMD News

GLMDGalmed Pharmaceuticals Ltd